AstraZeneca

For year ending Dec-2023, AstraZeneca annual Total revenue was 45,811 million USD and annual operating profit was 8,193 million USD and annual net income was 5,961 million USD.

AstraZeneca annual revenue was 44,351 million USD for year ending Dec-2022 and annual operating profit was 3,757 million USD and annual net income was 3,293 million USD for year ending Dec-2022.

AstraZeneca has 89,900 employees as of 2023. 

AstraZeneca has 83,500 employees as on 2022 when compared to with 76,100 employees as on 2020 and 70,600 employees as on 2019.

As on December-2022, AstraZeneca has 83,500 employees and out of that

• 16,500 employees are from USA.
• 10,700 employees are from UK
• 16,500 employees are from China
• 7,100 employees are from Sweden
• 11,400 employees are from Other Europe has
• 7,200 employees are from Other Asia Pacific
• 1,200 employees are from Canada and 2,400 employees are from Middle East and Africa and 2,000 employees are from Russia and 3,500 employees are from Japan and 1,000 employees are from Australia and New Zealand.

AstraZeneca company acquired Alexion Pharmaceuticals for 39 Billion USD in 2020.

AstraZeneca company highest selling drugs for year 2023

• Their largest selling products in the year were Farxiga ($5,963 million), 
• Tagrisso ($5,799 million), Imfinzi ($4,237 million), 
• Soliris ($3,145 million), and Ultomiris ($2,965 million). 
• Farxiga sales increased by 36% (CER: 39%), with continued volume growth across all major regions driven by launches in HF and CKD. 
• Tagrisso sales grew by 7% (CER: 9%) reflecting a strong performance from increased demand across all markets. I
• mfinzi Product Sales grew by 52% (CER: 55%), with increased use worldwide driven by new launches and established indications. 
• Soliris declined by 16% (CER: 14%) due to the successful conversion to Ultomiris, which increased by 51% (CER: 52%).